EGFR and breast carcinoma: Consistent with our finding, Jones et al reported that IGF-1R signalling pathway serves as a bypass for the EGFR-MAPK pathway, and is involved in the acquired resistance to gefitinib in a human breast cancer cell model (Jones et al, 2004).